Abstracts Archive - Page 1132 of 2425 - ACR Meeting Abstracts

Abstract Number: 1911 • 2018 ACR/ARHP Annual Meeting
The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Karyl Barron¹, Amanda Ombrello², Deborah Stone², Patrycja M. Hoffmann², Tina Romeo², Anne Jones³, Natalia Sampaio Moura², Oskar Schnappauf², Ivona Aksentijevich³, Jenna Bergerson¹, Ariane Soldatos⁴, Camilo Toro³, Theo Heller⁵, Jennifer Kanakry⁶, Katherine R Calvo⁷ and Daniel Kastner³, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²NHGRI, National Institutes of Health, Bethesda, MD, ³National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴NINDS, National Institutes of Health, Bethesda, MD, ⁵NIDDK, National Institutes of Health, Bethesda, MD, ⁶NCI, National Institutes of Health, Bethesda, MD, ⁷CC/DLM, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase 2 (DADA2) was initially described in 2014 in 2 reports: one emphasizing early-onset lacunar strokes, livedoid rash and intermittent…
Abstract Number: 1912 • 2018 ACR/ARHP Annual Meeting
Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs
Thomas Ballul¹, Raphaël Borie¹, Bruno Crestani¹, Eric Daugas¹, Vincent Descamps¹, Philippe Dieude¹, Antoine Dossier¹, Fabrice Extramiana¹, Thomas Papo¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: To analyze the efficacy of steroids and immunosuppressive drugs in the prevention of relapse in cardiac sarcoidosis. Methods: In this monocentric retrospective study, all…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Michael Richter¹, Cynthia S. Crowson², Lisa Kottschade³, Heidi Finnes³, Svetomir N. Markovic⁴ and Uma Thanarajasingam⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Oncology, Mayo Clinic, Rochester, MN, ⁴Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…
Abstract Number: 1915 • 2018 ACR/ARHP Annual Meeting
Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Soledad Retamozo^1,2,3, Alejandra Flores-Chavez^4,5,6, Belchin Kostov⁷, Antoni Sisó-Almirall⁸, Marta Pérez-de-Lis⁹, Roberto Pérez-Alvarez¹⁰, Pilar Brito-Zerón^11,12, Munther A Khamashta¹³ and Manuel Ramos-Casals¹⁴, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁵Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁶Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁷ABS Les Corts, CAPSE, Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁸Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, GESCLINIC, Barcelona, Barcelona, Spain, ⁹Department of Anesthesia, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain, ¹⁰Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹¹Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹³Lupus Research Unit, The Rayne Institute, Lupus Research Unit, The Rayne Institute, Kings' College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ¹⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona., Barcelona, Spain
Background/Purpose: The scenario of biological-triggered autoimmune diseases has dramatically changed in recent years due to the increasing use of biologics in patients with solid cancers. Methods:…
Abstract Number: 1916 • 2018 ACR/ARHP Annual Meeting
Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Christopher McMaster^1,2, David Liew^3,4, Pallavi Shamdasani⁵, Jessica Leung^3,4, Albert Frauman^6,7, Jonathan Cebon^7,8 and Russell Buchanan^4,9, ¹Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Australia, ²Health and Biomedical Informatics Centre, University of Melbourne, Parkville, Australia, ³Medicine, University of Melbourne, Parkville VIC, Australia, ⁴Rheumatology, Austin Health, Heidelberg VIC, Australia, ⁵Department of Rheumatology, Austin Health, Heidelberg, Australia, ⁶Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ⁷Medicine, University of Melbourne, Melbourne, Australia, ⁸Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia, ⁹Medicine, University of Melbourne, Parkville, Australia
Background/Purpose: Rheumatic immune-related adverse events (irAEs) from PD-1 inhibitor immune checkpoint immunotherapy can not only lead to cessation of immunotherapy, but also can be disabling…
Abstract Number: 1917 • 2018 ACR/ARHP Annual Meeting
Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
Yvonne C. Lee¹, Bing Lu², Hongshu Guan³, Jeffrey Greenberg⁴, Joel Kremer⁵ and Daniel Solomon⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Experts have implicated physician prescribing rates as a contributing factor to the opioid crisis. However, little is known about heterogeneity in these patterns and…
Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Yvonne C. Lee¹, Patricia Katz^2,3, Amanda Quebe⁴, Luna Sun⁴, Himanshu Patel⁴, Carol L. Gaich⁴, Natalie Boytsov⁴ and Kaleb Michaud^5,6, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ³University of California San Francisco, San Francisco, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…
Abstract Number: 1919 • 2018 ACR/ARHP Annual Meeting
Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
Cecilia P. Chung¹, S. Todd Callahan², William Cooper², William Dupont³, Katherine Murray¹, Andrew Franklin⁴, Kathi Hall⁵, Judith A. Dudley⁵, C. Michael Stein¹ and Wayne Ray⁵, ¹Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ⁴Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, ⁵Health Policy, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hydrocodone, codeine, oxycodone, and tramadol are frequently prescribed for moderate pain in adolescents. However, pharmacokinetic and pharmacodynamic differences between these short-acting opioids could affect…
Abstract Number: 1920 • 2018 ACR/ARHP Annual Meeting
Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
Priyanka Ballal¹, Joachim Scholz², Laura Frey-Law³, Na Wang¹, Michael C. Nevitt⁴, Cora E. Lewis⁵ and Tuhina Neogi⁶, ¹Boston University School of Medicine, Boston, MA, ²Departments of Anesthesiology and Pharmacology, Columbia University Medical Center, New York, NY, ³University of Iowa, Iowa City, IA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Self-reported descriptors of pain in knee osteoarthritis (OA) such as burning and stabbing pain are suggestive of a neuropathic component of pain beyond that…
Abstract Number: 1921 • 2018 ACR/ARHP Annual Meeting
Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain
Tuhina Neogi¹, Na Wang², Cora E. Lewis³, Michael C. Nevitt⁴ and Laura Frey-Law⁵, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³University of Alabama Birmingham, Birmingham, AL, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Iowa, Iowa City, IA
Background/Purpose: Alterations in pain processing, such as pain sensitization and inadequate conditioned pain modulation (CPM), may contribute to the observed pain persistence post-knee replacement (KR)…
Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
James Campbell, Randall Stevens and Peter Hanson, Centrexion Therapeutics, Boston, MA
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…
Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Elena Nikiphorou¹, Sam Norton², Adam Young³, Lewis Carpenter², Josh Dixey⁴, David Walsh⁵ and Patrick Kiely⁶, ¹Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, ²Academic Rheumatology, King's College London, London, United Kingdom, ³University of Hertfordshire, Hertford, United Kingdom, ⁴Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁶Rheumatology Dept, St Georges Hospital, London, Great Britain
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
Abstract Number: 1924 • 2018 ACR/ARHP Annual Meeting
Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
Maria I. Danila¹, Lang Chen¹, Justin K Owensby¹, Ronan O'Beirne¹, Joshua A. Melnick¹, Eric M. Ruderman², Leslie R. Harrold³ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Controlling disease activity in RA using a treat-to-target (T2T) strategy can optimize clinical and patient-important outcomes. Yet, many patients are not familiar with T2T…
Abstract Number: 1925 • 2018 ACR/ARHP Annual Meeting
Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?
Jennifer Barton^1,2, Shelia Markwardt², Allison Schue¹, Somnath Saha^2,3 and Edward H. Yelin⁴, ¹VA Portland Health Care System, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Medicine, VA Portland Health Care System, Portland, OR, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Goal concordance between patients with chronic diseases and their clinicians has been linked to improved outcomes, but not explored in rheumatoid arthritis (RA). Our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].